CYP3A4*22 Genotype-Guided Dosing of Kinase Inhibitors in Cancer Patients
ConclusionNon-inferiority could not be proven for dose reduction of KIs metabolized by CYP3A4 inCYP3A4*22 carriers compared to the registered dose in wildtype patients. Therefore, an up-front dose reduction based upon theCYP3A4*22 SNP for all KIs does not seem an eligible new way of personalized therapy.Trial RegistrationInternational Clinical Trials Registry Platform Search Portal; number NL7514; registered 11/02/2019. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - June 13, 2023 Category: Drugs & Pharmacology Source Type: research
A Joint Pharmacokinetic Model for the Simultaneous Description of Plasma and Whole Blood Tacrolimus Concentrations in Kidney and Lung Transplant Recipients
ConclusionWhole blood tacrolimus target ranges, currently used to guide TDM, were translated to plasma concentration ranges of 0.06 –0.26 ng/mL and 0.10–0.93 ng/mL for kidney and lung transplant recipients, respectively. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - June 12, 2023 Category: Drugs & Pharmacology Source Type: research
Use of Machine Learning for Dosage Individualization of Vancomycin in Neonates
ConclusionC0-based and AUC0 –24-based ML models were developed accurately and precisely. These can be used for individual dose recommendations of vancomycin in neonates before treatment and dose revision after the first TDM result is obtained, respectively. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - June 10, 2023 Category: Drugs & Pharmacology Source Type: research
Antifungal Dosing in Critically Ill Patients on Extracorporeal Membrane Oxygenation
This article discusses the available literature to inform adequate dosing of antifungals in this patient population. The number of antifungal PK studies in critically ill patients on ECMO is growing; currently available literature consists of case reports and studies with small sample sizes providing inconsistent findings, with scant or no data for some antifungals. Current data are insufficient to provide definitive empirical drug dosing guidance and use of dosing strategies derived from critically patients not on ECMO is reasonable. However, due to high PK variability, therapeutic drug monitoring should be considered whe...
Source: Clinical Pharmacokinetics - June 10, 2023 Category: Drugs & Pharmacology Source Type: research
Use of Machine Learning for Dosage Individualization of Vancomycin in Neonates
ConclusionC0-based and AUC0 –24-based ML models were developed accurately and precisely. These can be used for individual dose recommendations of vancomycin in neonates before treatment and dose revision after the first TDM result is obtained, respectively. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - June 10, 2023 Category: Drugs & Pharmacology Source Type: research
Antifungal Dosing in Critically Ill Patients on Extracorporeal Membrane Oxygenation
This article discusses the available literature to inform adequate dosing of antifungals in this patient population. The number of antifungal PK studies in critically ill patients on ECMO is growing; currently available literature consists of case reports and studies with small sample sizes providing inconsistent findings, with scant or no data for some antifungals. Current data are insufficient to provide definitive empirical drug dosing guidance and use of dosing strategies derived from critically patients not on ECMO is reasonable. However, due to high PK variability, therapeutic drug monitoring should be considered whe...
Source: Clinical Pharmacokinetics - June 10, 2023 Category: Drugs & Pharmacology Source Type: research
Pharmacokinetics, Pharmacodynamics and Safety of Janagliflozin in Chinese Type 2 Diabetes Mellitus Patients with Renal Impairment
ConclusionsThe exposure levels of janagliflozin in T2DM patients were slightly increased with worsening of RI (i.e., 11% increase in the AUC in patients with moderate RI compared with the normal renal function group). Despite worsening of renal function, janagliflozin exerted a significant pharmacologic effect and was well tolerated, even in patients with moderate RI, implying a promising role in the treatment of patients with in T2DM.Registration China Drug Trial register (http://www.chinadrugtrials.org.cn/I) identifier no.: CTR20192721. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - June 7, 2023 Category: Drugs & Pharmacology Source Type: research
Population Pharmacokinetics of Total Rabbit Anti-thymocyte Globulin in Non-obese Adult Patients Undergoing Hematopoietic Cell Transplantation for Hematologic Malignancy
ConclusionsThis novel popPK model described the PK of total rATG in the adult HCT patients who received a low-dose rATG conditioning regimen. This model can be used for model-informed precision dosing in the settings with minimal baseline rATG targets (T cells), and early clinical outcomes are of interest. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - June 7, 2023 Category: Drugs & Pharmacology Source Type: research
Pharmacokinetics, Pharmacodynamics and Safety of Janagliflozin in Chinese Type 2 Diabetes Mellitus Patients with Renal Impairment
ConclusionsThe exposure levels of janagliflozin in T2DM patients were slightly increased with worsening of RI (i.e., 11% increase in the AUC in patients with moderate RI compared with the normal renal function group). Despite worsening of renal function, janagliflozin exerted a significant pharmacologic effect and was well tolerated, even in patients with moderate RI, implying a promising role in the treatment of patients with in T2DM.Registration China Drug Trial register (http://www.chinadrugtrials.org.cn/I) identifier no.: CTR20192721. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - June 7, 2023 Category: Drugs & Pharmacology Source Type: research
Population Pharmacokinetics of Total Rabbit Anti-thymocyte Globulin in Non-obese Adult Patients Undergoing Hematopoietic Cell Transplantation for Hematologic Malignancy
ConclusionsThis novel popPK model described the PK of total rATG in the adult HCT patients who received a low-dose rATG conditioning regimen. This model can be used for model-informed precision dosing in the settings with minimal baseline rATG targets (T cells), and early clinical outcomes are of interest. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - June 7, 2023 Category: Drugs & Pharmacology Source Type: research
Genetic Factors Influencing Warfarin Dose in Han Chinese Population: A Systematic Review and Meta-Analysis of Cohort Studies
ConclusionThis is the first systematic review and meta-analysis assessing the association between single nucleotide polymorphisms (SNPs) of various genes known to influence MDWD besidesCYP2C9 andVKORC1 in the Han Chinese population.CYP4F2 (rs2108622),GGCX (rs12714145),EPHX1 (rs2292566 and rs2260863),ABCB1 (rs2032582),NQO1 (rs1800566), andCALU (rs2290228) SNPs might be moderate factors affecting MDWD requirements.Registered informationPROSPERO International Prospective Register of Systematic Reviews (CRD42022355130). (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - June 5, 2023 Category: Drugs & Pharmacology Source Type: research
